Literature DB >> 6343485

Isolation and identification of the third component of complement of Japanese quails.

C Kai, Y Yoshikawa, K Yamanouchi, H Okada.   

Abstract

The identification of the third component of complement (C3) of Japanese quails was attempted by using rabbit antiserum prepared against quail serum-treated zymosan (ZX) as an initial reagent. This antiserum (anti-ZX) had agglutinating activity on rabbit erythrocytes reacted with quail antibody and quail complement (EACq) but not on EAq, and developed two precipitin lines against quail serum at beta- and gamma-regions in crossed immunoelectrophoresis. Subsequently, monospecific antisera to each of these precipitin lines were prepared in rabbits, and quail serum proteins reactive with these antisera were purified by salt precipitation followed by Sephadex gel filtration and DEAE cellulose column chromatography. One protein with a m.w. of 184,000 (184K) resembled mammalian C3 in that: 1) monospecific antiserum (anti-184K protein serum) agglutinated EACq but not EAq; 2) treatment of fresh quail serum with either inulin or zymosan resulted in the conversion of the precipitin line developed against 184K protein from gamma to beta in crossed immunoelectrophoresis; 3) the 184K protein was shown to consist of two polypeptide chains of 110K and 73K linked by disulfide bonds. Furthermore, the 184K protein in serum was cleaved through the incubation with inulin to 174K and 140K proteins that might correspond to C3b and C3c of human complement; 4) the 184K protein bound to zymosan was eluted with hydrazine or methylamine but not with Nonidet P-40, indicating that 184K protein binds to zymosan by a covalent bond but not by a hydrophobic one; and 5) by treatment of fresh quail serum with methylamine, complement reactivity was reduced, although its activity was restored by the addition of purified 184K protein. These results suggest the 184K protein is the quail's equivalent to mammalian C3. When quail serum was reacted with cells that had complement-activating capacity, quail C3 deposited on their membrane as in mammalians; however, no conversion of quail C3 was noted by the reaction with CVF. Antibody to quail C3 failed to cross-react with that in mammals.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6343485

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Conservation of structural and functional domains in complement component C3 of Xenopus and mammals.

Authors:  D Grossberger; A Marcuz; L Du Pasquier; J D Lambris
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Ontogeny of the third component of complement of Japanese quails.

Authors:  C Kai; Y Yoshikawa; K Yamanouchi; H Okada; S Morikawa
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

3.  Complement-mediated hemolysis of horse erythrocytes treated with equine infectious anemia virus.

Authors:  H Sentsui; Y Kono
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

4.  Lysis of horse red blood cells mediated by antibody-independent activation of the alternative pathway of chicken complement.

Authors:  H Ohta; Y Yoshikawa; C Kai; K Yamanouchi; H Okada
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

5.  Activation of chicken alternative complement pathway by fowlpox virus-infected cells.

Authors:  H Ohta; C Kai; Y Yoshikawa; K Yamanouchi
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

6.  A soft tick Ornithodoros moubata salivary protein OmCI is a potent inhibitor to prevent avian complement activation.

Authors:  Amber M Frye; Thomas M Hart; Danielle M Tufts; Sanjay Ram; Maria A Diuk-Wasser; Peter Kraiczy; Anna M Blom; Yi-Pin Lin
Journal:  Ticks Tick Borne Dis       Date:  2019-12-06       Impact factor: 3.744

7.  Characterization of the fourth component of complement in the serum of the clawed frog Xenopus laevis.

Authors:  T Fujii; A Sekizawa; C Katagiri
Journal:  Immunology       Date:  1985-12       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.